default author photo

Rui Li

Tasly Biopharmaceuticals Co., Ltd - Department of Clinical Medicine

China

  • Tasly Biopharmaceuticals Co., Ltd - Department of Clinical Medicine

SCHOLARLY PAPERS

1

DOWNLOADS

0

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke within 4·5 Hours of Stroke Onset (PROST): A Phase 3, Randomised, Open-Label, Non-Inferiority Trial

Posted: 06 Jun 2022
Haiqing Song, Yuan Wang, Qingfeng Ma, Wuwei Feng, Rui Li, Xiaomei Lv, Lijuan Huang, Yi Yang, Deqin Geng, Jianguo Zhu, Yan Wei, Hui-Sheng Chen, Runxiu Zhu, Qijin Zhai, Jing Guo, Bo Liu, Shigang Zhao, Yuping Wang and PROST Collaborative Group
Capital Medical University - Department of Neurology, Capital Medical University - Department of Neurology, Capital Medical University - Department of Neurology, Duke University - Departments of Anesthesiology and Neurology, Tasly Biopharmaceuticals Co., Ltd - Department of Clinical Medicine, Tasly Biopharmaceuticals Co., Ltd - Department of Clinical Medicine, Tasly Biopharmaceuticals Co., Ltd - Department of Clinical Medicine, Jilin University (JLU) - Department of Neurology, Xuzhou Medical University - Department of Neurology, Harrison International Peace Hospital - Department of Neurology, Harrison International Peace Hospital, General Hospital of Northern Theater Command - Department of Neurology, Inner Mongolia People's Hospital - Department of Neurology, Xuzhou Medical University - Department of Neurology, Xuzhou Central Hospital - Department of Neurology, Baotou Medical College - Department of Neurology, Inner Mongolia Medical University - Department of Neurology, Capital Medical University - Department of Neurology and Independent

Abstract:

Loading...

acute ischemic stroke, thrombolytic, recombinant human prourokinase, alteplase